Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page footer now shows a newer revision label (v3.5.4), indicating a minor build update. This change does not modify the study details or other user-facing content.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page’s footer revision/version label has been updated from v3.5.2 to v3.5.3, reflecting a change in the site build rather than any study details.SummaryDifference0.1%

- Check37 days agoChange DetectedA new release version v3.5.2 was added and the previous v3.5.0 was removed.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded a citation to iRECIST guidelines in the references and removed the corresponding erratum note.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision: v3.5.0 was added to the page. Revision: v3.4.3 was removed from the page.SummaryDifference0.1%

- Check80 days agoChange DetectedUpdated the iRECIST guideline reference to the Lancet Oncol 2017 guidelines (version 3.4.3), replacing the older 3.4.2 citation.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.